prepared macrophage‐derived Exos‐coated poly(lactic‐co‐glycolic acid) nanoplatform for tumor‐targeted delivery of DOX, and then utilized a mesenchymal‐epithelial transition factor (c‐Met)‐targeting peptide to modify the Exos surface, because c‐Met is overexpressed by triple‐negative breast cancer cells.[246] The resultant nanoparticles showed robust tumor‐targeted delivery efficacy of DOX due to the dual tumor‐homing capabilities of macrophage‐derived Exos and c‐Met‐targeting peptide, which resulted in remarkable tumor cell apoptosis and regression of tumor growth. The gene discussed is MET; the disease is neoplasm.